MedTrace Logo

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

NCT07077083 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-11

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are:

* Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment?
* What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment?

Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.

Conditions

  • Clear Cell Renal Cell Carcinoma (ccRCC)
  • ccRCC

Interventions

DRUG

89Zr-Girentuximab

89Zr-Girentuximab PET

Sponsors & Collaborators

  • Telix Pharmaceuticals, Ltd

    collaborator UNKNOWN

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Shadi Abdar Esfahani, MD, MPH · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-16
Primary Completion
2027-08-01
Completion
2028-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07077083 on ClinicalTrials.gov